Vor Biopharma Inc. (VOR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
14/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseVOR / S&P 3.20% / 15.20% |
LoseVOR / S&P VOR unavailable / 15.00% |
LoseVOR / S&P -165.76% / 50.40% |
| 2026-Q12/3 |
WinVOR / S&P 36.39% / -4.33% |
LoseVOR / S&P VOR unavailable / 11.30% |
WinVOR / S&P 213.45% / 27.70% |
| 2025-Q41/3 |
LoseVOR / S&P -73.15% / 2.65% |
LoseVOR / S&P VOR unavailable / 9.00% |
WinVOR / S&P 298.36% / 13.40% |
| 2025-Q32/3 |
WinVOR / S&P 50.37% / 8.12% |
LoseVOR / S&P VOR unavailable / 4.61% |
WinVOR / S&P 4064.26% / 13.45% |
| 2025-Q22/3 |
WinVOR / S&P 125.63% / 10.94% |
LoseVOR / S&P VOR unavailable / 4.83% |
WinVOR / S&P 15696.53% / 10.63% |
| 2025-Q11/3 |
LoseVOR / S&P -35.32% / -4.27% |
LoseVOR / S&P VOR unavailable / 4.98% |
WinVOR / S&P 1168.36% / 10.57% |
| 2024-Q42/3 |
WinVOR / S&P 58.57% / 2.41% |
LoseVOR / S&P VOR unavailable / 5.25% |
WinVOR / S&P 910.86% / 6.15% |
| 2024-Q31/3 |
LoseVOR / S&P -30.00% / 5.89% |
LoseVOR / S&P VOR unavailable / 5.89% |
WinVOR / S&P 391.53% / 6.11% |
| 2024-Q20/3 |
LoseVOR / S&P -57.81% / 4.28% |
LoseVOR / S&P VOR unavailable / 5.38% |
LoseVOR / S&P -14.78% / 5.12% |
| 2024-Q10/3 |
LoseVOR / S&P 5.33% / 10.56% |
LoseVOR / S&P VOR unavailable / 5.71% |
LoseVOR / S&P -18.06% / 5.59% |
| 2023-Q40/3 |
LoseVOR / S&P 6.13% / 11.69% |
LoseVOR / S&P VOR unavailable / 6.81% |
LoseVOR / S&P -25.21% / 7.78% |
| 2023-Q30/3 |
LoseVOR / S&P -31.39% / -3.27% |
LoseVOR / S&P VOR unavailable / 7.52% |
LoseVOR / S&P -17.83% / -5.03% |
| 2023-Q21/3 |
LoseVOR / S&P -42.57% / 8.74% |
LoseVOR / S&P VOR unavailable / 9.50% |
WinVOR / S&P -6.45% / -8.57% |
| 2023-Q11/3 |
LoseVOR / S&P -19.10% / 7.50% |
LoseVOR / S&P VOR unavailable / 10.77% |
WinVOR / S&P 3.35% / -15.69% |
| 2022-Q41/3 |
WinVOR / S&P 67.09% / 7.56% |
LoseVOR / S&P VOR unavailable / 11.88% |
LoseVOR / S&P VOR unavailable / -17.99% |
| 2022-Q30/3 |
LoseVOR / S&P -19.92% / -4.88% |
LoseVOR / S&P VOR unavailable / 13.47% |
LoseVOR / S&P VOR unavailable / -1.41% |
| 2022-Q20/3 |
LoseVOR / S&P -17.72% / -16.10% |
LoseVOR / S&P VOR unavailable / 13.71% |
LoseVOR / S&P VOR unavailable / 11.04% |
| 2022-Q10/3 |
LoseVOR / S&P -48.02% / -4.60% |
LoseVOR / S&P VOR unavailable / 15.97% |
LoseVOR / S&P VOR unavailable / 42.23% |
| 2021-Q40/3 |
LoseVOR / S&P -25.89% / 11.03% |
LoseVOR / S&P VOR unavailable / 15.00% |
LoseVOR / S&P VOR unavailable / 96.40% |
| 2021-Q30/3 |
LoseVOR / S&P -15.92% / 0.58% |
LoseVOR / S&P VOR unavailable / 10.77% |
LoseVOR / S&P VOR unavailable / 69.42% |
| 2021-Q20/3 |
LoseVOR / S&P -56.73% / 8.55% |
LoseVOR / S&P VOR unavailable / 6.58% |
LoseVOR / S&P VOR unavailable / 51.81% |
| 2021-Q10/3 |
LoseVOR / S&P VOR unavailable / 6.17% |
LoseVOR / S&P VOR unavailable / -1.06% |
LoseVOR / S&P VOR unavailable / 7.39% |
| 2020-Q40/3 |
LoseVOR / S&P VOR unavailable / 12.15% |
LoseVOR / S&P VOR unavailable / -3.72% |
LoseVOR / S&P VOR unavailable / -33.42% |
| 2020-Q30/3 |
LoseVOR / S&P VOR unavailable / 8.93% |
LoseVOR / S&P VOR unavailable / -2.04% |
LoseVOR / S&P VOR unavailable / -27.10% |
| 2020-Q20/3 |
LoseVOR / S&P VOR unavailable / 20.54% |
LoseVOR / S&P VOR unavailable / -0.46% |
LoseVOR / S&P VOR unavailable / -27.11% |
| 2020-Q10/3 |
LoseVOR / S&P VOR unavailable / -19.60% |
LoseVOR / S&P VOR unavailable / 3.47% |
LoseVOR / S&P VOR unavailable / -14.75% |
| 2019-Q40/3 |
LoseVOR / S&P VOR unavailable / 9.07% |
LoseVOR / S&P VOR unavailable / 5.36% |
LoseVOR / S&P VOR unavailable / 2.99% |
| 2019-Q30/3 |
LoseVOR / S&P VOR unavailable / 1.70% |
LoseVOR / S&P VOR unavailable / 5.02% |
LoseVOR / S&P VOR unavailable / 0.21% |
| 2019-Q20/3 |
LoseVOR / S&P VOR unavailable / 4.30% |
LoseVOR / S&P VOR unavailable / 6.64% |
LoseVOR / S&P VOR unavailable / 8.65% |
| 2019-Q10/3 |
LoseVOR / S&P VOR unavailable / 13.65% |
LoseVOR / S&P VOR unavailable / 8.12% |
LoseVOR / S&P VOR unavailable / 14.29% |
| 2018-Q40/3 |
LoseVOR / S&P VOR unavailable / -13.52% |
LoseVOR / S&P VOR unavailable / 9.05% |
LoseVOR / S&P VOR unavailable / 18.23% |
| 2018-Q30/3 |
LoseVOR / S&P VOR unavailable / 7.71% |
LoseVOR / S&P VOR unavailable / 10.21% |
LoseVOR / S&P VOR unavailable / 19.06% |
| 2018-Q20/3 |
LoseVOR / S&P VOR unavailable / 3.43% |
LoseVOR / S&P VOR unavailable / 9.03% |
LoseVOR / S&P VOR unavailable / 14.46% |
| 2018-Q10/3 |
LoseVOR / S&P VOR unavailable / -0.76% |
LoseVOR / S&P VOR unavailable / 7.68% |
LoseVOR / S&P VOR unavailable / 12.46% |
| 2017-Q40/3 |
LoseVOR / S&P VOR unavailable / 6.64% |
LoseVOR / S&P VOR unavailable / 7.03% |
LoseVOR / S&P VOR unavailable / 13.82% |
| 2017-Q30/3 |
LoseVOR / S&P VOR unavailable / 4.48% |
LoseVOR / S&P VOR unavailable / 5.68% |
LoseVOR / S&P VOR unavailable / 17.57% |
| 2017-Q20/3 |
LoseVOR / S&P VOR unavailable / 3.09% |
LoseVOR / S&P VOR unavailable / 4.83% |
LoseVOR / S&P VOR unavailable / 17.74% |
| 2017-Q10/3 |
LoseVOR / S&P VOR unavailable / 6.07% |
LoseVOR / S&P VOR unavailable / 3.67% |
LoseVOR / S&P VOR unavailable / 13.32% |
| 2016-Q40/3 |
LoseVOR / S&P VOR unavailable / 3.82% |
LoseVOR / S&P VOR unavailable / 2.09% |
LoseVOR / S&P VOR unavailable / 7.05% |
| 2016-Q30/3 |
LoseVOR / S&P VOR unavailable / 3.85% |
LoseVOR / S&P VOR unavailable / 0.20% |
LoseVOR / S&P VOR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VOR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -40.28% | 20.78% |
| Annualized return | -40.28% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VOR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -92.06% | 83.14% |
| Annualized return | -39.75% | 12.86% |
10Y · 2021-02-05 to 2026-08-27
| Metric | VOR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.86% | 319.30% |
| Annualized return | -29.26% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |